Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

CHNA vs. VGHCX: which is better?

Bottom line

CHNA vs VGHCX: the short answer

CHNA (Loncar China BioPharma ETF) and VGHCX (Vanguard Health Care Fund) are both etfs.

Updated Nov 19, 2026

CHNA vs VGHCX side by side

CHNAVGHCX
TypeETFMutual fund
Fund familyGrayscaleVanguard
CategoryHealth Care SectorHealth Care Sector
Expense ratio—0.33%
Annual cost per $10k—$33
10-yr cost on $10k (prospectus)—$418
Max front loadNone0%
12b-1 fee—0%
1-yr return—+17.3%
5-yr return (annualized)—+6.6%
10-yr return (annualized)—+7.7%
Best quarter—+16.8%
Worst quarter—−12.3%
Net assets (fund)—$38.2B
Number of holdings—97
Portfolio turnover—47%
Returns as of—Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Holdings overlap

CHNA and VGHCX share none of their top holdings.

CHNA top 10

    VGHCX top 10

    1. Eli Lilly & Co — 8.61%
    2. Merck & Co Inc — 5.44%
    3. Johnson & Johnson — 4.83%
    4. AstraZeneca PLC — 4.59%
    5. UnitedHealth Group Inc — 4.05%
    6. Gsk Plc — 3.00%
    7. Edwards Lifesciences Corp — 2.56%
    8. Intuitive Surgical Inc — 2.52%
    9. CVS Health Corp — 2.52%
    10. Cencora Inc — 2.47%

    FAQ

    What is the difference between CHNA and VGHCX?
    CHNA (Loncar China BioPharma ETF) and VGHCX (Vanguard Health Care Fund) are both etfs.
    Should I own both CHNA and VGHCX?
    Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

    Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.